
LB Pharmaceuticals Inc: updates and filings
Price
$40.04
November 19, 2026Market cap $1.3B
What Ploutos Investor adds for LB Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
September 2026
August 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 5, 2026FilingFormEFFECT
- Oct 1, 2026FilingFormPOS AM
- Oct 1, 2026Shelf registration for future offeringsFormS-3ASR
- Sep 15, 2026Officer or director change, Regulation FD disclosureForm8-K
- Sep 3, 2026Officer or director change, Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 29, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosureForm8-K
- Jul 22, 2026Other material eventsForm8-K
- Jul 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 10, 2026Officer or director changeForm8-K
- Jun 9, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 5, 2026 | EFFECT | Filing | Document |
| Oct 1, 2026 | POS AM | Filing | Document |
| Oct 1, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Sep 15, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Sep 3, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 29, 2026 | 8-K | Material agreement entered, unregistered sale of shares, Regulation FD disclosure | Document |
| Jul 22, 2026 | 8-K | Other material events | Document |
| Jul 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 10, 2026 | 8-K | Officer or director change | Document |
| Jun 9, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 15, 2016.
The full analysis
What do LB Pharmaceuticals's filings show?
The filings are where every one of LB Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.